NYSE:TDOCHealthcare Services
Teladoc Health (TDOC): Ongoing Losses Persist, Testing Value Narrative at 0.6x Price-to-Sales
Teladoc Health (TDOC) remains unprofitable, with forecasts indicating no expectation of profitability over the next three years. The company has narrowed its losses at a 12% annual rate over the past five years, while revenue is projected to increase by 2.3% per year. This revenue growth rate trails the US market average of 10.3%. Despite ongoing net losses and a stagnant profit margin, shares currently trade at a Price-to-Sales Ratio of 0.6x. This is well below both the US Healthcare...